PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22911911-11	2010	CONCLUSION: The levels of serum pro-inflammatory cytokines IL-8 & TNF- alpha were significantly associated with subjects having respiratory symptoms & further supporting that they are inflammatory markers in respiratory symptoms.	Adenosine Monophosphate	65-68	tumor necrosis factor	Homo sapiens	70-80	
22911911-11	2010	CONCLUSION: The levels of serum pro-inflammatory cytokines IL-8 & TNF- alpha were significantly associated with subjects having respiratory symptoms & further supporting that they are inflammatory markers in respiratory symptoms.	Adenosine Monophosphate	154-157	tumor necrosis factor	Homo sapiens	70-80	
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	Adenosine Monophosphate	190-193	tumor necrosis factor	Homo sapiens	40-49	
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	Adenosine Monophosphate	190-193	tumor necrosis factor	Homo sapiens	262-271	
20102716-1	2010	BACKGROUND & AIMS: Pentoxifylline, an inhibitor of tumor necrosis factor-alpha, is given to patients with liver diseases, but its effects in patients with advanced cirrhosis are unknown.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	55-82	
17030185-1	2006	BACKGROUND & AIMS: Tumor necrosis factor (TNF) plays a critical role in intestinal disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-44	
20959025-2	2010	In the previous issue of Arthritis Research & Therapy, Kawabata and colleagues provided independent evidence that HDAC activity is increased in the synovium and fibroblast-like synoviocytes (FLSs) of patients with RA and is paralleled by increased HDAC1 expression and synovial tumor necrosis factor-alpha (TNFalpha) production.	Adenosine Monophosphate	45-48	tumor necrosis factor	Homo sapiens	282-309	
20959025-2	2010	In the previous issue of Arthritis Research & Therapy, Kawabata and colleagues provided independent evidence that HDAC activity is increased in the synovium and fibroblast-like synoviocytes (FLSs) of patients with RA and is paralleled by increased HDAC1 expression and synovial tumor necrosis factor-alpha (TNFalpha) production.	Adenosine Monophosphate	45-48	tumor necrosis factor	Homo sapiens	311-319	
19000449-1	2008	BACKGROUND & OBJECTIVE: The expression of TNF-like weak inducer of apoptosis (TWEAK) in breast cancer remains disputable.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	46-49	
19591638-4	2009	In the current issue of Arthritis Research & Therapy, Hueber and colleagues become the first to present a multi-parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment.	Adenosine Monophosphate	44-47	tumor necrosis factor	Homo sapiens	207-210	
18242213-1	2008	BACKGROUND & AIMS: Ligation of tumor necrosis factor (TNF) receptors (TNFRs) with TNF plays a critical role in the pathogenesis of human inflammatory bowel disease (IBD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	58-61	
18242213-1	2008	BACKGROUND & AIMS: Ligation of tumor necrosis factor (TNF) receptors (TNFRs) with TNF plays a critical role in the pathogenesis of human inflammatory bowel disease (IBD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	74-77	
17631138-1	2007	BACKGROUND & AIMS: Infliximab induces immune cell apoptosis by outside-to-inside signaling through transmembrane tumor necrosis factor-alpha (mTNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	117-138	
17030185-1	2006	BACKGROUND & AIMS: Tumor necrosis factor (TNF) plays a critical role in intestinal disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	46-49	
16904065-4	2006	On the other hand, the inhibitory effect of ATP on TNF-alpha release was completely reversed by 5"-AMPS (a P2Y11 receptor antagonist) as well as by H-89, an inhibitor of cAMP-activated PKA.	Adenosine Monophosphate	96-103	tumor necrosis factor	Homo sapiens	51-60	
16687074-1	2006	BACKGROUND & OBJECTIVE: Tumor necrosis factor alpha (TNF-alpha) is an important agent for tumor biotherapy because of its strong antitumor activity, but its clinical application is limited because of its severe fatal systemic toxicity.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	28-55	
16687074-1	2006	BACKGROUND & OBJECTIVE: Tumor necrosis factor alpha (TNF-alpha) is an important agent for tumor biotherapy because of its strong antitumor activity, but its clinical application is limited because of its severe fatal systemic toxicity.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	57-66	
16472588-1	2006	BACKGROUND & AIMS: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-44	
16734992-8	2006	RESULTS: Both mean TNF-alpha and IL-6 were increased following S&RP ; however, the observed increases were not statistically significant.	Adenosine Monophosphate	65-68	tumor necrosis factor	Homo sapiens	19-28	
10930380-1	2000	BACKGROUND & AIMS: The tumor necrosis factor (TNF)-alpha/TNF receptor system is critical for liver development because hepatocytes undergo apoptosis if the antiapoptotic cascades resulting in RelA NF-kappaB activation are not effective.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	27-60	
17282113-1	2005	TNFα stimulates SPHK in the monocyte, which leads to the expression of adhesion molecules on the cell surface.	Adenosine Monophosphate	4-7	tumor necrosis factor	Homo sapiens	0-3	
17282113-3	2005	In this paper, we have delineated the TNFα-induced and SPHK-dependent signaling pathway.	Adenosine Monophosphate	42-45	tumor necrosis factor	Homo sapiens	38-41	
17282113-4	2005	In addition, we have developed a biomathematical model to qualify the SPHK time-dependent activity at a specific site in the cell upon TNFα stimulation.	Adenosine Monophosphate	139-142	tumor necrosis factor	Homo sapiens	135-138	
12943802-9	2003	It is an acyclic nucleoside analogue of adenosine monophosphate that also happens to increase TNF.	Adenosine Monophosphate	40-63	tumor necrosis factor	Homo sapiens	94-97	
12917036-1	2003	BACKGROUND & OBJECTIVE: Acute lymphocytic leukemia(ALL), which is sensitive to tumor necrosis factor (TNF) is one of hematological malignances derived from lymphoid tissue.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	83-104	
12917036-1	2003	BACKGROUND & OBJECTIVE: Acute lymphocytic leukemia(ALL), which is sensitive to tumor necrosis factor (TNF) is one of hematological malignances derived from lymphoid tissue.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	106-109	
14609050-8	2003	INTERPRETATION & CONCLUSION: The results indicate that ivIg reduces the serum TNF-alpha concentrations in the GBS patients having elevated levels prior to ivIg therapy.	Adenosine Monophosphate	16-19	tumor necrosis factor	Homo sapiens	82-91	
12606947-9	2003	The suppression of TNF-induced NF-kappaB activation was unique to adenosine, as neither its metabolites (inosine, AMP, and ATP) nor pyrimidines (thymidine and uridine) had any effect.	Adenosine Monophosphate	114-117	tumor necrosis factor	Homo sapiens	19-22	
11313318-1	2001	BACKGROUND & AIMS: Recent studies suggest that major histocompatibility complex-encoded susceptibility to primary sclerosing cholangitis (PSC) maps to the HLA B-TNFA region on chromosome 6p21.3.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	165-169	
15135700-2	2004	The increased conversion of adenosine monophosphate to adenosine, which in turn attenuates the expression of tumor necrosis factor-alpha (TNF-alpha) expression, has been suggested as a putative mechanism for prolonged survival in patients with congestive heart failure (CHF) carrying the mutant AMPD1 allele.	Adenosine Monophosphate	28-51	tumor necrosis factor	Homo sapiens	109-136	
15135700-2	2004	The increased conversion of adenosine monophosphate to adenosine, which in turn attenuates the expression of tumor necrosis factor-alpha (TNF-alpha) expression, has been suggested as a putative mechanism for prolonged survival in patients with congestive heart failure (CHF) carrying the mutant AMPD1 allele.	Adenosine Monophosphate	28-51	tumor necrosis factor	Homo sapiens	138-147	
11677207-1	2001	BACKGROUND & AIMS: Treatment with a chimeric anti-tumor necrosis factor (TNF) antibody (infliximab) has been shown to be highly efficient for patients with steroid-refractory Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	49-75	
11677207-1	2001	BACKGROUND & AIMS: Treatment with a chimeric anti-tumor necrosis factor (TNF) antibody (infliximab) has been shown to be highly efficient for patients with steroid-refractory Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	77-80	
10930380-1	2000	BACKGROUND & AIMS: The tumor necrosis factor (TNF)-alpha/TNF receptor system is critical for liver development because hepatocytes undergo apoptosis if the antiapoptotic cascades resulting in RelA NF-kappaB activation are not effective.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	50-53	
10579967-1	1999	BACKGROUND & AIMS: Inhibition of tumor necrosis factor is a proposed mechanism for the anti-inflammatory properties of thalidomide.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	37-58	
28008484-3	2000	By contrast, they showed the potential to up- or down-regulate the production of TNF evoked by PMA & ionomycin, which was strongly dependent on the time of the stimulation.	Adenosine Monophosphate	100-103	tumor necrosis factor	Homo sapiens	81-84	
11005615-3	2000	By contrast, they showed the potential to up- or down-regulate the production of TNF evoked by PMA & ionomycin, which was strongly dependent on the time of the stimulation.	Adenosine Monophosphate	100-103	tumor necrosis factor	Homo sapiens	81-84	
10579968-1	1999	BACKGROUND & AIMS: Thalidomide decreases production of tumor necrosis factor alpha, a proinflammatory cytokine associated with Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	59-86	
9869598-1	1999	BACKGROUND & AIMS: Anti-tumor necrosis factor alpha monoclonal antibody treatment (infliximab) reduces clinical signs and symptoms in patients with Crohn"s disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	28-55	
10529838-1	1999	TNF-alpha was investigated by bioassay and ELISA in the supernatant of the cultures challenged with 100 ng/mL, 500 ng/mL, 1 and 2 &mgr;g/mL of venom.	Adenosine Monophosphate	131-134	tumor necrosis factor	Homo sapiens	0-9	
7506004-3	1993	In this study we investigated whether the novel anti-inflammatory drug, SK&F 86002 [5-4(-pyridyl)-6(4-fluorophenyl)-2,3-dihydroimidazole(2,1-b)thi azol] and related analogs of the pyridinyl imidazole class, inhibit IL-1 and TNF production via a cAMP-dependent mechanism.	Adenosine Monophosphate	75-78	tumor necrosis factor	Homo sapiens	228-231	
7797011-1	1995	BACKGROUND & AIMS: Increased concentrations of tumor necrosis factor (TNF), a potent proinflammatory cytokine, can be shown in the mucosa of patients with active Crohn"s disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	51-72	
7797011-1	1995	BACKGROUND & AIMS: Increased concentrations of tumor necrosis factor (TNF), a potent proinflammatory cytokine, can be shown in the mucosa of patients with active Crohn"s disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	74-77	
31237169-8	2019	Incubation of immune cells, obtained from post- CA subjects, with AMP , a substrate for CD 73, resulted in inhibition of tumor necrosis factor-alpha production and generation of reactive oxygen species.	Adenosine Monophosphate	66-69	tumor necrosis factor	Homo sapiens	121-148	
34758308-2	2021	Here, we demonstrate that TNF triggers a type-I interferon response that is dependent on the cyclic guanosine monophosphate-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway.	Adenosine Monophosphate	124-127	tumor necrosis factor	Homo sapiens	26-29	
31442600-1	2020	BACKGROUND & AIMS: It is important to objectively assess Crohn`s disease (CD) activity in patients treated with antibodies against tumor necrosis factor (anti-TNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	135-156	
31442600-1	2020	BACKGROUND & AIMS: It is important to objectively assess Crohn`s disease (CD) activity in patients treated with antibodies against tumor necrosis factor (anti-TNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	163-166	
31401142-1	2019	BACKGROUND & AIMS: Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody against tumor necrosis factor (TNF), in treatment of immune-mediated diseases, including inflammatory bowel diseases.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	145-166	
31401142-1	2019	BACKGROUND & AIMS: Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody against tumor necrosis factor (TNF), in treatment of immune-mediated diseases, including inflammatory bowel diseases.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	168-171	
30056180-1	2019	BACKGROUND & AIMS: Antagonists of tumor necrosis factor (TNF) are effective for induction and maintenance of remission of Crohn"s disease (CD) and are generally prescribed when patients do not respond to conventional, less-costly medical therapies.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	38-59	
30056180-1	2019	BACKGROUND & AIMS: Antagonists of tumor necrosis factor (TNF) are effective for induction and maintenance of remission of Crohn"s disease (CD) and are generally prescribed when patients do not respond to conventional, less-costly medical therapies.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	61-64	
30547786-15	2018	TNFalpha treatment elicited strong induction of the chemokine CXCL8, the kinases MAP3K8, MAP4K4 and negative regulators of cytokine signaling, i.e. SOCS2&SOCS3.	Adenosine Monophosphate	154-157	tumor necrosis factor	Homo sapiens	0-8	
30692075-7	2019	Pharmacological inhibition of TNF-alpha-induced autophagy by 3-MA significantly decreased the cell viability and increased the apoptosis rate of SCAPs (P < 0.05).	Adenosine Monophosphate	155-158	tumor necrosis factor	Homo sapiens	30-39	
29980311-1	2019	BACKGROUND & AIM: Tumor necrosis factor-alpha (TNF-alpha) and its genetic variants are implicated in the development of type 2 diabetes (T2D) as a result of systemic inflammation, dyslipidemia, and insulin resistance.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	22-49	
29980311-1	2019	BACKGROUND & AIM: Tumor necrosis factor-alpha (TNF-alpha) and its genetic variants are implicated in the development of type 2 diabetes (T2D) as a result of systemic inflammation, dyslipidemia, and insulin resistance.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	51-60	
30630559-16	2019	On the 1st day after the RFA, the level of TNF-α, IL-6 in Group A were lower than those of Group B (all p<0.001).	Adenosine Monophosphate	48-51	tumor necrosis factor	Homo sapiens	43-46	
29702293-1	2018	BACKGROUND & AIMS: Tumor necrosis factor (TNF) antagonists are the first-line treatment for many autoimmune diseases.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-44	
29702293-1	2018	BACKGROUND & AIMS: Tumor necrosis factor (TNF) antagonists are the first-line treatment for many autoimmune diseases.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	46-49	
30701887-1	2018	AIM: To clarify the association between HLA-DRB1 and TNFalpha (-308G>A) genes polymorphism and joint destruction/further progression during 12 months of the follow-up period (FUP) in patients with early (<6 months), active, predominantly antibodies to cyclic citrullinated peptide (ACCP) and rheumatoid factor (RF)-positive rheumatoid arthritis (RA) treated according to "Treat to target" strategy.	Adenosine Monophosphate	69-72	tumor necrosis factor	Homo sapiens	53-61	
29631379-13	2018	NEW & NOTEWORTHY Our findings show that tumor necrosis factor-alpha inhibits intestinal ascorbic acid uptake in both in vitro and in vivo systems, and this inhibitory effect is mediated, at least in part, at the level of transcription of the SLC23A1 (sodium-dependent vitamin C transporter-1) gene via the NF-kappaB pathway.	Adenosine Monophosphate	5-8	tumor necrosis factor	Homo sapiens	44-71	
29976865-4	2018	We tested the effects of phloretin on tumor necrosis factor (TNF)-α production induced by various TLRs using known TLR-specific agonists.	Adenosine Monophosphate	67-70	tumor necrosis factor	Homo sapiens	38-59	
29976865-4	2018	We tested the effects of phloretin on tumor necrosis factor (TNF)-α production induced by various TLRs using known TLR-specific agonists.	Adenosine Monophosphate	67-70	tumor necrosis factor	Homo sapiens	61-64	
29932162-6	2018	EAH also suppressed the translocation of inflammation transcription factors such as NF-κB p65 in TNF-α/IFN-γ-stimulated HaCaT cells.	Adenosine Monophosphate	88-91	tumor necrosis factor	Homo sapiens	107-110	
29932162-6	2018	EAH also suppressed the translocation of inflammation transcription factors such as NF-κB p65 in TNF-α/IFN-γ-stimulated HaCaT cells.	Adenosine Monophosphate	112-115	tumor necrosis factor	Homo sapiens	107-110	
30701887-1	2018	AIM: To clarify the association between HLA-DRB1 and TNFalpha (-308G>A) genes polymorphism and joint destruction/further progression during 12 months of the follow-up period (FUP) in patients with early (<6 months), active, predominantly antibodies to cyclic citrullinated peptide (ACCP) and rheumatoid factor (RF)-positive rheumatoid arthritis (RA) treated according to "Treat to target" strategy.	Adenosine Monophosphate	212-215	tumor necrosis factor	Homo sapiens	53-61	
30701887-6	2018	Real time polymerase chain reaction (PCR-RT) was used for TNFalpha gene polymorphism (-308G>A) genotyping.	Adenosine Monophosphate	92-95	tumor necrosis factor	Homo sapiens	58-66	
30701887-9	2018	RESULTS: As for TNFalpha gene polymorphism, it was demonstrated that the number of narrowings and total Sharp score values were almost twice as high at baseline in GG genotype carriers as compared to GA genotype carriers (r<0,005, and r<0,004 respectively).	Adenosine Monophosphate	224-227	tumor necrosis factor	Homo sapiens	16-24	
30701887-12	2018	CONCLUSION: Our data suggest that HLA-DRB1 (SE+) gene and TNFalpha (-308G>A) polymorphisms are associated with the progression of radiographic joint destruction in early, active RA patients managed according to "Treat to target" stratagy.	Adenosine Monophosphate	74-77	tumor necrosis factor	Homo sapiens	58-66	
30701887-12	2018	CONCLUSION: Our data suggest that HLA-DRB1 (SE+) gene and TNFalpha (-308G>A) polymorphisms are associated with the progression of radiographic joint destruction in early, active RA patients managed according to "Treat to target" stratagy.	Adenosine Monophosphate	219-222	tumor necrosis factor	Homo sapiens	58-66	
30701887-12	2018	CONCLUSION: Our data suggest that HLA-DRB1 (SE+) gene and TNFalpha (-308G>A) polymorphisms are associated with the progression of radiographic joint destruction in early, active RA patients managed according to "Treat to target" stratagy.	Adenosine Monophosphate	219-222	tumor necrosis factor	Homo sapiens	58-66	
28103201-1	2017	BACKGROUND & AIMS: Considering the ability of anti-TNF alpha drugs to lower the burden intestinal inflammation in patients with inflammatory bowel disease (IBD), and the similarity between IBD and ankylosing spondylitis (AS) regarding inflammatory intestinal involvement, we aimed to investigate the impact of anti-TNF alpha biologic therapy on subclinical intestinal inflammation in AS patients.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	55-64	
30267490-13	2018	Main group saw a decrease in TNF-alpha levels from 10,14±0,6 to 7,49±0,33 pg/ml (<0,001) and IL-6 levels from 11,12±0,7 to 7,84±0,62 pg/ml (<0,001).	Adenosine Monophosphate	57-60	tumor necrosis factor	Homo sapiens	29-38	
30267490-13	2018	Main group saw a decrease in TNF-alpha levels from 10,14±0,6 to 7,49±0,33 pg/ml (<0,001) and IL-6 levels from 11,12±0,7 to 7,84±0,62 pg/ml (<0,001).	Adenosine Monophosphate	78-81	tumor necrosis factor	Homo sapiens	29-38	
30267490-13	2018	Main group saw a decrease in TNF-alpha levels from 10,14±0,6 to 7,49±0,33 pg/ml (<0,001) and IL-6 levels from 11,12±0,7 to 7,84±0,62 pg/ml (<0,001).	Adenosine Monophosphate	78-81	tumor necrosis factor	Homo sapiens	29-38	
30267490-13	2018	Main group saw a decrease in TNF-alpha levels from 10,14±0,6 to 7,49±0,33 pg/ml (<0,001) and IL-6 levels from 11,12±0,7 to 7,84±0,62 pg/ml (<0,001).	Adenosine Monophosphate	78-81	tumor necrosis factor	Homo sapiens	29-38	
28750089-3	2017	One cationic AMP, GW-A2, demonstrated the ability to inhibit the expression levels of nitric oxide (NO), inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in lipopolysaccharide (LPS)-activated macrophages.	Adenosine Monophosphate	13-16	tumor necrosis factor	Homo sapiens	161-188	
28750089-3	2017	One cationic AMP, GW-A2, demonstrated the ability to inhibit the expression levels of nitric oxide (NO), inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in lipopolysaccharide (LPS)-activated macrophages.	Adenosine Monophosphate	13-16	tumor necrosis factor	Homo sapiens	190-199	
29751535-7	2018	Furthermore, IL-1β-stimulated SW982 cells secreted less inflammatory cytokines (TNF-α and IL-6), which is associated with the downregulation of p38-mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and NF-κB pathways.	Adenosine Monophosphate	18-21	tumor necrosis factor	Homo sapiens	89-92	
28823863-1	2017	BACKGROUND & AIMS: Diarrhea associated with inflammatory bowel diseases has been associated with increased levels of inflammatory cytokines, including tumor necrosis factor (TNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	155-176	
28823863-1	2017	BACKGROUND & AIMS: Diarrhea associated with inflammatory bowel diseases has been associated with increased levels of inflammatory cytokines, including tumor necrosis factor (TNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	178-181	
28456632-1	2017	BACKGROUND & AIMS: Tumor necrosis factor (TNF) is an inflammatory cytokine expressed by human fetal liver cells (HFLCs) after infection with cell culture-derived hepatitis C virus (HCV).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-44	
28456632-1	2017	BACKGROUND & AIMS: Tumor necrosis factor (TNF) is an inflammatory cytokine expressed by human fetal liver cells (HFLCs) after infection with cell culture-derived hepatitis C virus (HCV).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	46-49	
27997918-8	2017	CONCLUSION: Genetic variation of the TNFalpha rs1800629 might be useful as a biomarker in clinical decision-making since it was found to be related to cancer risk, tumor recurrence, and survival of H&N cancer patients.	Adenosine Monophosphate	200-203	tumor necrosis factor	Homo sapiens	37-45	
27647233-2	2017	METHODS: A meta-analysis was performed to examine the association between the TNF-alpha -308 G>A and LT-alpha +252 A>G polymorphisms and the incidence of leukemia.	Adenosine Monophosphate	95-98	tumor necrosis factor	Homo sapiens	78-87	
27647233-2	2017	METHODS: A meta-analysis was performed to examine the association between the TNF-alpha -308 G>A and LT-alpha +252 A>G polymorphisms and the incidence of leukemia.	Adenosine Monophosphate	124-127	tumor necrosis factor	Homo sapiens	78-87	
27997918-8	2017	CONCLUSION: Genetic variation of the TNFalpha rs1800629 might be useful as a biomarker in clinical decision-making since it was found to be related to cancer risk, tumor recurrence, and survival of H&N cancer patients.	Adenosine Monophosphate	204-207	tumor necrosis factor	Homo sapiens	37-45	
28344879-11	2017	TNFalpha production by CD73+ CD14+ cells was significantly impaired in the presence of AMP, confirming immunosuppressive function.	Adenosine Monophosphate	87-90	tumor necrosis factor	Homo sapiens	0-8	
26890234-11	2016	Bound monocytes within P-selectin positive and tissue factor positive complexes correlate positively with intracoronary TNF-alpha (r = 0.81, p = 0.008 & r = 0.80, p = 0.009 respectively) and IL-6 (r = 0.54, p = 0.16 & r = 0.71, p = 0.05 respectively).	Adenosine Monophosphate	152-155	tumor necrosis factor	Homo sapiens	120-129	
26890234-11	2016	Bound monocytes within P-selectin positive and tissue factor positive complexes correlate positively with intracoronary TNF-alpha (r = 0.81, p = 0.008 & r = 0.80, p = 0.009 respectively) and IL-6 (r = 0.54, p = 0.16 & r = 0.71, p = 0.05 respectively).	Adenosine Monophosphate	221-224	tumor necrosis factor	Homo sapiens	120-129	
25131534-1	2015	BACKGROUND & AIMS: Antagonists of tumor necrosis factor (anti-TNF agents) can cause drug-induced liver injury (DILI), yet little is known about the level of risk.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	38-59	
26896085-15	2016	CONCLUSIONS: Anti-TNF therapy responders and non-responders display distinctly separate patterns of mucosal AMP expression and gut microbiota before treatment start.	Adenosine Monophosphate	108-111	tumor necrosis factor	Homo sapiens	18-21	
27042444-12	2016	Our study shows Negative Correlation between MDA and SOD in case & control groups, while a Positive Correlation between TNF alpha and IL-6 in control & case groups.	Adenosine Monophosphate	155-158	tumor necrosis factor	Homo sapiens	124-133	
26939244-9	2015	A significant correlation between CSF-TNF and each of ESR (P=003) & CSF cells (P=0.015), without significant correlation regarding other parameters (P>0.05).	Adenosine Monophosphate	67-70	tumor necrosis factor	Homo sapiens	38-41	
27189916-1	2016	BACKGROUND & AIMS: The availability of tests for blood concentrations of anti-tumor necrosis factor (TNF) agents and antibodies against these drugs could improve dose selection for patients with inflammatory bowel disease (IBD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	77-103	
27058635-1	2016	BACKGROUND & AIMS: Inhibitors of tumor necrosis factor (anti-TNF agents) are the most effective therapy for Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	37-58	
27058635-1	2016	BACKGROUND & AIMS: Inhibitors of tumor necrosis factor (anti-TNF agents) are the most effective therapy for Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	65-68	
27275202-8	2015	In comparing the pre &post acupuncture results of TNF-alpha, IL-6 and hsCRP showed high significant reduction after acupuncture.	Adenosine Monophosphate	22-25	tumor necrosis factor	Homo sapiens	54-63	
24268978-1	2014	BACKGROUND & AIMS: Anti-tumor necrosis factors (anti-TNF) including infliximab, adalimumab and certolizumab pegol are used to treat Crohn"s disease (CD) and ulcerative colitis (UC).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	57-60	
25898559-8	2015	RESULTS: DP-M&O decreased the levels of TNF-alpha, IL-1beta, IL-6, and IL-8 and increased that of IL-10 in a concentration-dependent manner.	Adenosine Monophosphate	14-17	tumor necrosis factor	Homo sapiens	44-53	
25898559-9	2015	Significant differences were found between the 20% P-M&O and PAg groups in the release of the inflammatory cytokines TNF-alpha (70.8 +/- 22.3 vs. 277.1 +/- 65.5, P < 0.01) , IL-113 (277.5 +/- 22.6 vs. 630.4 +/- 89.7, P <0.01), IL-6 (232.7 +/- 62.7 vs. 994.2 vs. 182.3, P < 0.01), IL-8 (227.3 +/- 79.2 vs. 769.3 +/- 284.1, P < 0.01), and IL-10 (640.2 +/- 201.2 vs. 271.1 +/- 55.8, P < 0.01).	Adenosine Monophosphate	55-58	tumor necrosis factor	Homo sapiens	121-130	
24813174-1	2014	BACKGROUND & AIMS: Therapeutic antibodies against tumor necrosis factor alpha (anti-TNF) are effective in patients with Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	54-81	
24813174-1	2014	BACKGROUND & AIMS: Therapeutic antibodies against tumor necrosis factor alpha (anti-TNF) are effective in patients with Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	88-91	
25344180-3	2014	RESULTS: Serum concentrations of TNF-α, IL-6 and Gal-3 in both the severe and mild groups were significantly higher than in the control group before treatment.	Adenosine Monophosphate	38-41	tumor necrosis factor	Homo sapiens	33-36	
25344180-6	2014	CONCLUSIONS: Serum TNF-α, IL-6 and Gal-3 play important roles in the occurrence and development of pediatric MPP and their levels are associated the severity of this disorder.	Adenosine Monophosphate	24-27	tumor necrosis factor	Homo sapiens	19-22	
24604047-8	2014	INTERPRETATION & CONCLUSIONS: Collectively, our data indicate that fluvastatin induces apoptotic cell death in TNFalpha-stimulated SW982 human synovial cells through the inactivation of the geranylgerenylated membrane fraction of RhoA and Rac1 proteins and the subsequent inhibition of the PI3K/Akt signaling pathway.	Adenosine Monophosphate	16-19	tumor necrosis factor	Homo sapiens	115-123	
24393049-6	2014	The log serum levels of TNF-alpha & IL-4 at 16-18 weeks of gestation were significantly higher in women with periodontal disease (4.13 +- 2.06; 0.47 +- 1.56 pg/ml respectively) than in women with healthy gums (2.16 +- 1.51; 0.02 +- 1.84 pg/ml respectively, p < 0.001).	Adenosine Monophosphate	35-38	tumor necrosis factor	Homo sapiens	24-33	
24078983-1	2013	BACKGROUND & AIM: Incremental increase in the risk of serious infections with combinations of tumor necrosis factor-alpha (TNF-alpha) inhibitors and immunomodulators compared to monotherapy with these agents in inflammatory bowel disease (IBD) is unclear.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	98-125	
24498926-0	2013	"Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".	Adenosine Monophosphate	15-18	tumor necrosis factor	Homo sapiens	88-115	
24078983-1	2013	BACKGROUND & AIM: Incremental increase in the risk of serious infections with combinations of tumor necrosis factor-alpha (TNF-alpha) inhibitors and immunomodulators compared to monotherapy with these agents in inflammatory bowel disease (IBD) is unclear.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	127-136	
24198887-2	2013	CRP& TNF-alpha, are acute phase proteins monitored as a marker of inflammatory status, which have been identified as a major risk factor for atherosclerotic complications.	Adenosine Monophosphate	4-7	tumor necrosis factor	Homo sapiens	9-18	
23965971-5	2013	Irradiated HEM cells had the greatest fold of TNFalpha secretion (UVB: 109-fold, UVA + B: 103-fold & UVB+A: 130-fold) when co-exposed to IL1alpha.	Adenosine Monophosphate	100-103	tumor necrosis factor	Homo sapiens	46-54	
24198887-3	2013	Elevated CRP & TNF-alpha level in periodontitis patients have been reported by several groups.	Adenosine Monophosphate	14-17	tumor necrosis factor	Homo sapiens	19-28	
24198887-4	2013	The present study was performed to determine whether presence of periodontitis and periodontal therapy could influence the serum levels of CRP & TNF-alpha in cardiovascular disease patients.	Adenosine Monophosphate	144-147	tumor necrosis factor	Homo sapiens	149-158	
23717605-8	2013	The results showed that the variant genotype and allele of TNFalpha -308A/G was protective in pooled groups of patients with PsV&PsA (OR = 0.682, 0.750; 95% CI, 0.596-0.779, 0.653-0.861).	Adenosine Monophosphate	129-132	tumor necrosis factor	Homo sapiens	59-67	
23717605-9	2013	However, the variant genotypes and alleles of TNFalpha -238A/G and -857T/C had an increased risk of PsV&PsA (OR = 2.493, 2.228, 1.536, 1.486, 95% CI, 1.777-3.498, 1.628-3.049, 1.336-1.767, 1.309-1.685).	Adenosine Monophosphate	104-107	tumor necrosis factor	Homo sapiens	46-54	
24080827-14	2013	This work should establish a new signaling pathway linking alcohol, ER stress, and TNF-alpha to loss of bone formation: Ethanol   ER stress      ATF4 & CHOP      TNF-alpha      Osteoblasts   .	Adenosine Monophosphate	151-154	tumor necrosis factor	Homo sapiens	83-92	
23333219-1	2013	BACKGROUND & AIMS: Tumor necrosis factor (TNF)-alpha antagonists have been associated with drug-induced liver injury (DILI).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-56	
23703343-13	2013	INTERPRETATION & CONCLUSIONS: Our preliminary results indicated that G allele at TNF-alpha - 308 was more common in TA patients and controls similar to that in other Indian as well as Japanese population.	Adenosine Monophosphate	16-19	tumor necrosis factor	Homo sapiens	85-94	
23200982-1	2013	BACKGROUND & AIMS: Some women with inflammatory bowel disease require therapy with tumor necrosis factor (TNF) antagonists during pregnancy.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	87-108	
23555696-6	2013	This combination was more effective in inducing RNase 7 than the combination of IL-17A/TNF-alpha, a combination previously identified as a strong inducer of psoriasis-related immune response genes including several AMP.	Adenosine Monophosphate	215-218	tumor necrosis factor	Homo sapiens	87-96	
21605007-4	2011	RESULTS: At baseline, the purines AMP and hypoxanthine correlated with multiple inflammatory markers including neutrophil counts and the cytokines interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-alpha), and IL-1beta (r ranged from 0.41 to 0.66, all P < 0.05).	Adenosine Monophosphate	34-37	tumor necrosis factor	Homo sapiens	173-200	
22624049-7	2012	AMP strongly inhibited secretion of TNF-alpha and IL-12p70, while it enhanced production of IL-10 both via activation of A(2a) receptors.	Adenosine Monophosphate	0-3	tumor necrosis factor	Homo sapiens	36-45	
21875498-1	2011	BACKGROUND & AIMS: The anti-tumor necrosis factor (TNF) antibodies infliximab, adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn"s disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	55-58	
21642014-1	2011	BACKGROUND & AIMS: Certolizumab pegol (CZP) is a pegylated-conjugated Fab" against tumor necrosis factor (TNF).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	110-113	
21334460-1	2011	BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to treat patients with moderate to severe Crohn"s disease (CD).	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	57-84	
23059571-0	2012	Estimation of the level of tumor necrosis factor- alpha in gingival crevicular fluid and serum in periodontal health & disease: A biochemical study.	Adenosine Monophosphate	118-121	tumor necrosis factor	Homo sapiens	27-55	
22382194-13	2012	INTERPRETATION & CONCLUSIONS: Our results suggest the possible role of TNF-alpha in the pathogenesis of type-2 diabetes mellitus and the importance of reducing obesity to prevent elevated levels of the cytokine and related complications.	Adenosine Monophosphate	16-19	tumor necrosis factor	Homo sapiens	75-84	
21875498-1	2011	BACKGROUND & AIMS: The anti-tumor necrosis factor (TNF) antibodies infliximab, adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn"s disease.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	27-53	
21050341-0	2011	Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-alpha in HCV & HCV/HIV infection.	Adenosine Monophosphate	14-17	tumor necrosis factor	Homo sapiens	76-85	
21605007-4	2011	RESULTS: At baseline, the purines AMP and hypoxanthine correlated with multiple inflammatory markers including neutrophil counts and the cytokines interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-alpha), and IL-1beta (r ranged from 0.41 to 0.66, all P < 0.05).	Adenosine Monophosphate	34-37	tumor necrosis factor	Homo sapiens	202-211	
21486440-0	2011	Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.	Adenosine Monophosphate	77-80	tumor necrosis factor	Homo sapiens	67-75	
21486440-0	2011	Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.	Adenosine Monophosphate	102-105	tumor necrosis factor	Homo sapiens	67-75	
21486440-6	2011	Significant associations were found between CCL2 & CCL5 and TNFalpha & IL-1beta in the tumor cells in DCIS and IDC-no-relapse patients.	Adenosine Monophosphate	50-53	tumor necrosis factor	Homo sapiens	64-72	
21486440-7	2011	In the IDC-with-relapse group, the expression of CCL2 & CCL5 was accompanied by further elevated incidence of TNFalpha & IL-1beta expression.	Adenosine Monophosphate	55-58	tumor necrosis factor	Homo sapiens	114-122	
21486440-7	2011	In the IDC-with-relapse group, the expression of CCL2 & CCL5 was accompanied by further elevated incidence of TNFalpha & IL-1beta expression.	Adenosine Monophosphate	124-127	tumor necrosis factor	Homo sapiens	114-122	
21146893-1	2011	BACKGROUND & AIMS: Excessive apoptosis and leukocyte-dependent inflammation mediated by pro-inflammatory cytokines, such as TNFalpha, are cardinal features of acute liver injury.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	128-136	
20955706-1	2011	BACKGROUND & AIMS: Anti-tumor necrosis factor (TNF)alpha antibodies are effective in treating patients with Crohn"s disease whereas soluble TNFalpha receptors have not shown clinical efficacy; the mechanism that underlies these different effects is not clear.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	28-49	
21186276-0	2011	Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK.	Adenosine Monophosphate	117-120	tumor necrosis factor	Homo sapiens	112-115	
21071479-0	2011	Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study.	Adenosine Monophosphate	76-79	tumor necrosis factor	Homo sapiens	71-74	
20800309-1	2010	BACKGROUND & AIMS: TNF was the first cytokine employed for cancer therapy, but its use was limited due to its insufficient selectivity towards malignant cells.	Adenosine Monophosphate	12-15	tumor necrosis factor	Homo sapiens	23-26	
20725112-6	2010	In the HBF group, a positive correlation was observed between TNF-α and IL-6, IL-10 and the proinflammatory cytokines, and IL-6 and glycemia.	Adenosine Monophosphate	67-70	tumor necrosis factor	Homo sapiens	62-65